Audit confirms effectiveness of Cambridge cancer diagnostic pathway
A Cambridge company has been independently identified as an increasingly influential player in the safe and rapid diagnosis of cancer.
Check4Cancer, which has offices at Copley Hill Business Park, was awarded ‘Diagnostics provider of the year’ at the 2018 Health Investor Awards at the Grosvenor Hotel, London.
Chief medical officer Professor Gordon Wishart then further underlined the potential of the company’s technology when he presented audit results from its private breast cancer diagnosis pathway to the Association of Breast Surgery annual conference in Birmingham at the start of this week.
Check4Cancer enables people to take ownership of their health, and that of their family, by providing cancer services that are described as innovative, validated and effective.
The company’s team of cancer specialists has extensive clinical expertise, enabling Check4Cancer to provide award-winning services trusted by leading UK insurance providers and corporate sector clients.
Check4Cancer partners with companies in the UK, US & Europe, facilitating the offering of cancer screening and awareness as an employee benefit. Existing corporate clients include the BBC, Novartis, Sky, VW, Deloitte, HP, Lendlease, Unicredit, Nissan, Volvo and Zurich.
At the UK conference, Professor Wishart described that how using lessons learned from the Ian Paterson breast surgeon scandal in Birmingham, he developed a safe pathway where all investigations, including biopsy, are performed on the same day.
This best practice One Stop pathway is now delivered by a network of breast surgeons throughout the UK. All surgeons are vetted before being allowed to join the network and they must report the investigations performed and results from each case.
The new audit of over 1000 patients confirmed that 88 per cent of women seen without GP referral could be reassured and discharged on the same day.
The average time to the first appointment attended was 3.8 days and the average feedback score was 99/100. Women with breast symptoms can therefore be reassured that this private service is safe, fast and offers 100% compliance with NICE guidelines for best practice, Professor Wishart said.
He added: “While there can be no guarantee that another Paterson-type scandal wont occur, I am delighted that Check4Cancer has given patients rapid access to an accurate and reliable diagnosis, reducing average times to be seen and improving patients’ experience in the private sector.
“Having just won Best Diagnostics Provider at the Health Investor Awards last week, it is rewarding to now have these results selected for presentation at the annual breast surgery conference.”
The awards judges praised Check4Cancer for its “high quality patient-centred, medically led service with clear targets for an effective one-stop approach diagnostic pathway” and its “level of clinical audit underpinning the outcomes.”
Accepting the award, Professor Wishart, said: “We are thrilled to have been recognised for our commitment to patient focused, reliable early cancer detection.
“Our best practice diagnostic pathways for breast & skin cancer have given patients rapid access to an accurate and reliable diagnosis, reducing average times to diagnosis and improving patients’ experience.”
Check4Cancer covers bowel, breast, cervical, lung, prostate and skin cancer for the private, insured and corporate markets.
Founded in 2007, Check4Cancer’s nationwide, evidence-based services are supported by audit data and cover 87 per cent of all new cancer incidence in the UK every year. Services can be accessed at over 80 clinics across the UK.
• PHOTOGRAPH SHOWS: Professor Gordon Wishart (chief medical officer) and Jackie Wishart (director) of Check4Cancer